Authorization

TRACON Pharmaceuticals to Present at the BTIG Virtual Biotechnology Conference

SAN DIEGO, Aug. 03, 2020 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (Nasdaq: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and utilizing a cost efficient, CRO-independent product development platform to partner with ex-U.S. companies to develop and commercialize innovative products in the U.S., announced today that Charles Theuer, M.D., Ph.D., President and CEO, will present a corporate overview at the 2020 BTIG Virtual Biotechnology Conference on Monday, August 10th, at 11:30 am EDT.
To access a live webcast of the presentation, please visit the a??Events and Presentationsa?? page within the a??Investorsa?? section of the TRACON Pharmaceuticals website at www.traconpharma.com.About TRACONTRACON develops targeted therapies for cancer utilizing a capital efficient, CRO independent, product development platform. The Companya??s clinical-stage pipeline includes: Envafolimab, a subcutaneous PD-L1 single-domain antibody being developed for the treatment of sarcoma with the goal of initiating a registrational trial in the U.S. in the fourth quarter of 2020; TRC253, a small molecule drug candidate for the treatment of prostate cancer; TRC102, a Phase 2 small molecule drug candidate being developed for the treatment of lung cancer; and TJ004309, a CD73 antibody in Phase 1 development for the treatment of advanced solid tumors. A TRACON is actively seeking additional corporate partnerships whereby it leads U.S. regulatory and clinical development and shares in the cost and risk of clinical development and leads U.S. commercialization.A  In these partnerships TRACON believes it can serve as a solution for companies without clinical and commercial capabilities in the U.S.A  To learn more about TRACON and its product pipeline, visit TRACON's website at www.traconpharma.com.

Company Contact:



Investor Contact:



Mark Wiggins



Andrew McDonald



Chief Business Officer



LifeSci Advisors LLC



(858) 251-3492



646-597-6987



mwiggins@traconpharma.com



Andrew@lifesciadvisors.com
See also:
Leave a comment
News
  • Latest
  • Read
  • Commented
Calendar Content
«    Декабрь 2020    »
ПнВтСрЧтПтСбВс
 123456
78910111213
14151617181920
21222324252627
28293031